FY2025 · ended Dec 31, 2025 · Revenue $2.31B, +35.9% YoY · Filed Feb 27, 2026
Natera, Inc. (NTRA) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.3 billion and a net loss of $208.2 million. Free cash flow was $109.1 million. As of Jun 30, 2026 it held $2.2 billion in cash and investments and $238.5 million in total debt.
Revenue (TTM)
$2.71B
+37.8% vs year-ago TTM
Net income (TTM)
$-192.35M
+24.0% vs year-ago TTM
Operating cash flow (TTM)
$228.24M
+22.2% vs year-ago TTM
Free cash flow (TTM)
$84.20M
-19.5% vs year-ago TTM
EPS (TTM)
$-1.37
+28.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
141.73M
+4.8% vs prior year
Net cash
$1.94B
as of Jun 30, 2026
Operating margin
-10.7%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- NTRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1604821
- Former names
- Natera, Inc. (until Nov 5, 2026)
Other Services-Medical Laboratories companies
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.3B | $1.7B | $1.1B | $820.2M | $625.5M |
| Operating income | -$309.9M | -$222.3M | -$446.2M | -$541.0M | -$468.2M |
| Net income | -$208.2M | -$190.4M | -$434.8M | -$547.8M | -$471.7M |
| Diluted EPS | -$1.52 | -$1.53 | -$3.78 | -$5.57 | -$5.21 |
| Operating cash flow | $215.3M | $135.7M | -$247.0M | -$431.5M | -$335.2M |
| Free cash flow | $109.1M | $69.2M | -$286.2M | -$479.2M | -$376.3M |
| Total assets | $2.4B | $1.7B | $1.4B | $1.4B | $1.2B |
| Total liabilities | $685.9M | $465.3M | $676.4M | $688.7M | $583.2M |
| Stockholders' equity | $1.7B | $1.2B | $765.3M | $705.7M | $653.3M |
| Cash and investments | $1.1B | $968.3M | $879.0M | $898.4M | $914.5M |
| Total debt | $214.4M | $187.1M | $442.0M | $446.2M | $397.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 6, 2026 | Jul 1, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jun 16, 2026 | Jun 2, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 16, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 5, 2026 | Jun 2, 2026 |
All 1001 Natera, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.